|Application ||WB, ICC/IF|
|Description||Rabbit Anti-Human GLUT2 Polyclonal|
|Target/Specificity||Predicted molecular weight at ~57.5kDa. Observed molecular weight at 60-70kDa and 38-45kDa.|
|Other Names||Glucose Transporter 2 Antibody, Glucose Transporter GLUT2 Antibody, BLUT-2 Antibody, GTR_Human Antibody, SLC2a2 Antibody, Solute Carrier Family 2 (facilitated glucose transporter) member 2 Antibody|
|Immunogen||Synthetic peptide from the C-terminal of human GLUT2|
|Purification||Peptide Affinity Purified|
|Storage Buffer||PBS, 50% glycerol, 0.09% sodium azide|
|Shipping Temperature||Blue Ice or 4ºC|
|Certificate of Analysis||A 1:1000 dilution of SPC-697 was sufficient for detection of GLUT2 on 293T Rapamycin-treated lysates using Goat anti-rabbit IgG:HRP as the secondary antibody.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Glucose transporter 2 (GLUT2) also known as solute carrier family 2 (facilitated glucose transporter), member 2 (SLC2A2) is a transmembrane carrier protein that enables protein facilitated glucose movement across cell membranes. It is the principal transporter for transfer of glucose between liver and blood, and has a role in renal glucose reabsorption (1). Mutations in SLC2A2 lead to Fanconi-Bickel syndrome (FBS), which results in hepatorenal glycogen accumulation, proximal renal tubular dysfunction, and impaired utilization of glucose and galactose. Recent studies have shown that mutations in SLC2A2 can cause neonatal diabetes, and therefore may contribute to human insulin secretion (2). Novel SLC2A2 mutations have also been discovered and are being investigated to determine their roles in FBS as well (3).
1. Kellett G.L., Brot-Laroche E. (2005) Diabetes. 54(10): 3056-3062.
2. Sansbury F.H., et al. (2012) Diabetologia. 55(9): 2381-2385.
3. Su Z., et al. (2011) J Perdiatr Endocrinol Metab. 24(9-10): 749-753.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.
Request Quote Here